London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Surely, whatever anyone says the key to everything for Scancell now is Data Data Data.
To coin a phrase not DATES but DATA.
Once we have that (from whatever platform/prduct) we will then have something to evaluate.
Then and only then can the Share Price prevailing at that stage be judged to be too low, too high or maybe (in a non bearish way) Just right.
The market can't know what the right level is at the moment, and "Guessing" where the Share Price is going in the next few days is a mug's game in my opinion.
We all know what we hope for but the operative word is HOPE.
I shall try and remember that as I read the apparently informed ( but often unfulfilled) predictions of those here who claim to understand the market better than anyone else.
Put simply, No one knows what will happen until it has.
DYOR
LL,
That doesn't take into account the convertible loan notes, so 14.6 "fully diluted"
""We also know a big partner will not come in until SCLP demonstrate p1 results. So boils down to how confident SCLP are in Vax.""
Do we?????
Miavoce
Absolutely spot on
Morning.
Kraft I think a very balanced post of yours in explaining situation.
We know SCLP need a big partner to take this forward not only to finance p3 but also to scale up manu which we know is easier with DNA.
We also know a big partner will not come in until SCLP demonstrate p1 results. So boils down to how confident SCLP are in Vax.
My take I don’t think there is a done deal but would imagine there has been interest as they will know about SCLP and I can’t see SCLP putting so much effort into it purely on anticipation of a deal and although p1 results will produce human data they are not going to be large enough to make a compelling take to market done deal so it may be enough to take it into p2 and see then re evaluate the results at that stage.
Plus of course the possible option of doing p2 Human Challenge studies
Morning all...
The presentation was just a roadmap for shareholders and tying the loose ends and not an RNS!
CH to my pleasant surprise did just that ...job well done in my books.
GL
Jeez there is some serious overthinking going on here. This was one of a regular series of Turner Pope webinars featuring their clients which will be aimed as much at promoting Turner Pope as at promoting the company itself. The emphasis on the fundraise elements was testament to this.
Regarding the timing - probably been in the diary for a while.
Why vague about details and nothing new. ? Because they always are - they have to be very careful not to give away anything which may be price sensitive.
Why dull ? Because that is how Cliff does things.
Certainly can't see a specific need for the presentation, although interesting to hear the optimistic view on the restarting of cancer trials. The covidity timeline was intriguing - as if something is brewing and is so close. Time will tell, but you can see the confidence and reassurance that now exists with a big heap of cash on hand and the influence of Redmile.
"...So I am a little confused with mixed signals.<"
This. The tin foil hat wearing conspiracy nutter In me almost makes me think this was deliberate. What was the actual aim of the presentation? It was very short notice, and do Scancell really need to attract new PI investors? Only big pharma partnering will make a difference now, no?
A deliberate ploy to allow someone big to buy in cheaper? Yes, yes, I'll go and take my meds now.
C7, I think it was slide 19, Anticipated Newsflow - short to medium term.
2021 H1 expected news
SCIB1: Study centres activated
Modi1: First-in-Human study planned to start
Covid-19 was classed as asap... with selection of lead candidate SN15/SCOV1, preclinical testing against SARS CoV-2 variants, completion of GMP manu., and initiation of safety assessment in humans (CT1 I think).
Ruck, 17.7 was the last valuation I read by TD.
C7, I'll look out my notes after a cuppa.
I thought it was all a bit vague on that front. However we fund phase 1. Big Partner required for phase 2/3. Bit cloak and dagger as manufacturing is taking place presumably for phase 1 as per SKY and we physically saw it. So I am a little confused with mixed signals. Long term all looks totally fabulous and by beginning of next year with cancer trial results confirmed we will be a different company even without Covidity. But if we get a push up on valuation with Covidity this year gives us a higher SP as the springboard and base for those crucial negotiations for partners with Immunobody and Moditope.
LL,
14.6p per share?
I should hope not.
Morning LL, what timelines did CH put on it in the presentation??
Ray, I do not think Scancell's IPs is worth anything less than the valuation Trinity Delta put on it. Cliff was very clear about when news could be expected in the presentation last night.
Lindy won't be able to sleep tonight after today's fall in the US market :-)
Does anyone seriously think that the IP of the company will be worth less tomorrow?
there is nothing to worry about - 3 trials starting this year, at least one within weeks, Avidimab progressing nicely, talking to big pharma.
So everything going to plan and timescales holding up well.
What's not to like? Don't really think there will be a fall in the sp, but I will be up early to hit the Buy button if there is!